BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone1-646-305-6387
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/22/2019 (Estimated)
OptionableNot Optionable
Beyondspring (NASDAQ:BYSI) Frequently Asked Questions
What is Beyondspring's stock symbol?
Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."
How were Beyondspring's earnings last quarter?
Beyondspring Inc (NASDAQ:BYSI) released its quarterly earnings results on Wednesday, September, 18th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.05. View Beyondspring's Earnings History.
When is Beyondspring's next earnings date?
What price target have analysts set for BYSI?
2 brokers have issued 1 year price targets for Beyondspring's stock. Their predictions range from $35.00 to $41.00. On average, they anticipate Beyondspring's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 121.4% from the stock's current price. View Analyst Price Targets for Beyondspring.
What is the consensus analysts' recommendation for Beyondspring?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beyondspring.
What are Wall Street analysts saying about Beyondspring stock?
Here are some recent quotes from research analysts about Beyondspring stock:
- 1. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (10/17/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $41 price target. All of our current valuation is based on the opportunity for Plinabulin with 84% contribution coming from neutropenia and the remainder for NSCLC (higher risk indication). Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, Plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (9/18/2019)
- 3. Maxim Group analysts commented, "BeyondSpring reported 3Q18 (on 10/23) with expenses of $12.4M. The company ended the period with a cash balance of $22.4M. The company has runway into early 2019 though we expect BYSI needs to raise capital. Combined with the recent pullback in valuation, driven in part by macro factors such as contracting multiples in the healthcare space, we lower our price target to $35, from $48 – still plenty of upside." (10/25/2018)
Has Beyondspring been receiving favorable news coverage?
News stories about BYSI stock have trended extremely negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Beyondspring earned a news sentiment score of -4.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Beyondspring.
Are investors shorting Beyondspring?
Beyondspring saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 551,700 shares, an increase of 9.4% from the August 30th total of 504,200 shares. Based on an average daily volume of 49,100 shares, the short-interest ratio is presently 11.2 days. Approximately 6.9% of the shares of the stock are short sold. View Beyondspring's Current Options Chain.
Who are some of Beyondspring's key competitors?
Some companies that are related to Beyondspring include Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Radius Health (RDUS), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), Dicerna Pharmaceuticals (DRNA), Endo International (ENDP) and ArQule (ARQL).
What other stocks do shareholders of Beyondspring own?
Who are Beyondspring's key executives?
Beyondspring's management team includes the folowing people:
- Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 48)
- Mr. Dongheng Liu, Chief Financial Officer (Age 37)
- Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 58)
- Dr. Ramon W. Mohanlal, Exec. VP of R&D and Chief Medical Officer (Age 61)
- Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 75)
When did Beyondspring IPO?
(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.
Who are Beyondspring's major shareholders?
Beyondspring's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.03%).
Which institutional investors are buying Beyondspring stock?
BYSI stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC.
How do I buy shares of Beyondspring?
Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Beyondspring's stock price today?
One share of BYSI stock can currently be purchased for approximately $17.16.
How big of a company is Beyondspring?
What is Beyondspring's official website?
How can I contact Beyondspring?
Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]
MarketBeat Community Rating for Beyondspring (NASDAQ BYSI)
MarketBeat's community ratings are surveys of what our community members think about Beyondspring and other stocks. Vote "Outperform" if you believe BYSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
